MARKET

ZLAB

ZLAB

Zai Lab Limited
NASDAQ
16.02
-0.17
-1.05%
After Hours: 16.00 -0.02 -0.12% 16:22 03/28 EDT
OPEN
16.43
PREV CLOSE
16.19
HIGH
16.43
LOW
15.96
VOLUME
780.64K
TURNOVER
0
52 WEEK HIGH
40.42
52 WEEK LOW
15.69
MARKET CAP
1.59B
P/E (TTM)
-4.6266
1D
5D
1M
3M
1Y
5Y
Zai Lab Partner Novocure's Metis Phase 3 Trial Meets Primary Endpoint In Brain Metastases
NASDAQ · 1d ago
NovoCure climbs after late-stage win for lung cancer therapy
NovoCure climbs after late-stage win for lung cancer therapy. The oncology company said that a Phase 3 trial for its cancer therapy reached its primary endpoint in patients with brain metastases resulting from lung cancer. Novocure shares surged 31% premarket Thursday.
Seeking Alpha · 2d ago
Weekly Report: what happened at ZLAB last week (0318-0322)?
Weekly Report · 4d ago
Weekly Report: what happened at ZLAB last week (0311-0315)?
Weekly Report · 03/18 11:24
Buy Rating Affirmed for Zai Lab Amid Strong Sales Performance and Positive Development Outlook
TipRanks · 03/15 09:16
Zai Lab To Present Findings From Preclinical Studies Highlighting ZL-1310, A Novel Antibody-Drug Conjugate (ADC) For Treatment Of Solid Tumors
Benzinga · 03/14 06:38
Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors
Zai Lab will present findings from preclinical studies of ZL-1310 at the European Lung Cancer Congress 2024 in March 2024 in Prague, Czech Republic. The preclinical data will highlight the therapeutic potential of the company’s next-generation antibody-drug conjugate (ADC) program. Zl- 1310 is a novel and promising ADC targeting the Delta-like ligand 3 (DLL3) in the treatment of small cell lung cancer.
Barchart · 03/13 18:05
KB Financial, BeiGene, Legend Biotech among premarket gainers' pack
ShiftPixy (PIXY) and Minim (MINM) among premarket gainers' pack. KB Financial, BeiGene, Legend Biotech among the biggest morning stock movers. Biggest gainers in SA on the day were ShiftPixY and ShiftPIXy.
Seeking Alpha · 03/13 12:29
More
About ZLAB
Zai Lab Ltd is a holding company mainly engaged in the biopharmaceutical field. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including oncology, autoimmune and infectious diseases fields. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include Niraparib (ZL-2306), ZL-2103, ZL-1101 and others.

Webull offers Zai Lab Ltd - ADR stock information, including NASDAQ: ZLAB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZLAB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ZLAB stock methods without spending real money on the virtual paper trading platform.